Celltrion USA has finalized its application for a biosimilar approval, targeting CT-P47, a counterpart to the drug ACTEMRA® (tocilizumab).

European Commission Sanctions Takeda's HYQVIA® for Ongoing Treatment in Chronic Inflammatory Demyelinating Polyneuropathy Cases.

U.S. authorities expedite assessment of ENHERTU® for individuals suffering from advanced solid cancers with HER2-positive status.

Nivolumab plus hyaluronidase administered beneath the skin is comparably effective to Opdivo given intravenously for advanced or metastatic clear cell kidney cancer as suggested by study CheckMate -67T.

On Jan 26, Pfizer and Astellas Pharma announced that the European Medicines Agency (EMA) has accepted to review a Type II variation application for the combined use of PADCEV® and KEYTRUDA®.

KEYTRUDA® (Pembrolizumab) Enhances Disease-Free Survival (DFS) as Adjuvant in High-Risk Urothelial Carcinoma Post-Surgery.

Dupixent® has been granted FDA approval as the exclusive therapy indicated for pediatric patients over the age of 1 diagnosed with eosinophilic esophagitis (EoE).

Orion Presents New Insights from Phase II CYPIDES Trial on ODM-208 at 2024 ASCO Symposium.

CBR-701 (SYS6002), a cutting-edge therapeutic agent aimed at Nectin-4, exhibits promising outcomes in initial human trials with Nectin-4 positive cancer patients.

Flare Therapeutics Unveils Design for FX-909's Early-Stage Trial with Dose Increasing and Widening Approach at ASCO's 2024 Urologic Cancer Conference.

LAVA Therapeutics reveals a partnership with Merck & Co., US, to assess the potential of combining LAVA-1207 with the treatment, KEYTRUDA®.

Sionna Therapeutics has revealed the administration of the initial dose to a healthy participant in the Stage 1 clinical study for SION-109.